Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.
OBJECTIVE
Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.


METHODS
One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m(2)) or cisplatin (60 mg/m(2)) was given over 1 hour with 5-FU (1 gm/m(2)) on days 1~5 every 4 weeks.


RESULTS
At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.


CONCLUSIONS
Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.
Lee
Kyung Hee
KH
Korea Cancer Study Group, College of Medicine, Yeungnam University, Daegu, Korea.
Hyun
Myung Soo
MS
Kim
Hoon-Kyo
HK
Jin
Hyung Min
HM
Yang
Jinmo
J
Song
Hong Suk
HS
Do
Young Rok
YR
Ryoo
Hun Mo
HM
Chung
Joo Seop
JS
Zang
Dae Young
DY
Lim
Ho-Yeong
HY
Jin
Jong Youl
JY
Yim
Chang Yeol
CY
Park
Hee Sook
HS
Kim
Jun Suk
JS
Sohn
Chang Hak
CH
Lee
Soon Nam
SN
J Med Chem. 1994 May 13;37(10):1471-85
8182706
Br J Cancer. 1989 Nov;60(5):767-9
2803953
Cancer Treat Rev. 1985 Sep;12 Suppl A:1-19
3910215
Ann Intern Med. 1984 May;100(5):704-13
6370067
J Clin Oncol. 2003 Jan 1;21(1):54-9
12506170
CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47
11814064
Cancer Treat Rev. 1985 Sep;12 Suppl A:21-33
3910219
Cancer. 1993 Jun 15;71(12):3813-8
8508349
Br J Cancer. 1991 Oct;64(4):788-92
1911229
Clin Pharmacol Ther. 1979 Mar;25(3):351-7
761445
Cancer. 1981 Jan 1;47(1):207-14
7459811
J Korean Med Sci. 2004 Jun;19(3):369-73
15201502
CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
11577478
Anticancer Res. 1995 Jan-Feb;15(1):51-4
7733640
Curr Opin Oncol. 1992 Dec;4(6):1073-9
1457521
Cancer Chemother Pharmacol. 1998;41(2):109-16
9443623
Cancer. 1999 Oct 1;86(7):1109-15
10506693
J Clin Oncol. 1986 Jul;4(7):1053-7
3014083
Cancer Res Treat. 2005 Apr;37(2):79-86
19956484
Eur J Cancer. 1994;30A(14):2091-3
7857709
Am J Med. 1978 Aug;65(2):307-14
99034
Cancer Chemother Pharmacol. 1995;37(1-2):1-6
7497577
Cancer Chemother Pharmacol. 2002 Aug;50(2):104-10
12172973
Cancer Chemother Pharmacol. 1995;35(5):441-5
7850928